Coherus Oncology, Inc.

CHRS Healthcare Biotechnology

In the quarter to June 2026, revenue grew 39.5%, EPS fell 105.1%, free cash flow fell 33.2% and total debt rose 1.03%, each against the same quarter a year earlier.

1.00 0.07 −6.54%
Market cap
$165.3M
P/E
0.0×
Fwd P/E
−1.4×
Dividend yield
—
F-score
6/9
Altman Z
−8.83
Beneish M
−3.44
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
P/E ratio

+8 more quarters

1.23 0.97 1.01 0.00
P/S ratio
5.13 3.94 4.92 4.26
P/FCF ratio
0.00 0.00 0.00 0.00
P/Operating CF
(4.11) (8.44) (3.98) (3.49)
P/B ratio
2.17 2.73 2.93 3.56
EV/Sales
5.68 4.89 5.88 6.35
EV/EBITDA
0.00 0.00 0.00 0.00
EV/FCF
(2.31) (1.48) (1.61) (1.73)
Current Ratio
1.24 1.47 1.56 1.77
Net Debt/EBITDA
3.57 3.00 3.68 2.16
Debt/Equity
0.42 0.61 0.47 0.61
Earnings Yield
81.10% 102.82% 98.82% (73.57%)
Free Cash Flow Yield
(47.81%) (83.84%) (74.41%) (86.26%)
Free Cash Flow per Share
(0.40) (0.17) (0.42) (0.40)
Book value per Share
0.76 0.52 0.58 0.39
Free Cash Flow
(46.34) (19.72) (57.89) (62.09)
EV/EBIT
0.00 0.00 0.00 0.00
Other line items

Show all line items

Columns are period end dates